Lonza Sets New Mid Term Targets
Swiss drug maker Lonza has announced new mid term targets and confirmed its full year outlook. The company expects steady growth as it prepares to finalize a major divestment.
Xurve View
Insights:
Xurve View
LONZA GROUP AG-REG set new mid-term targets and confirmed its 2026 outlook on Wednesday ahead of its capital markets day, pointing to stable third-quarter performance across its business areas. The Switzerland-based contract drug manufacturer is positioning itself as a pure-play operator following the pending divestment of its capsules unit. The strategy aims to capture rising demand in biologics manufacturing through organic growth and disciplined dealmaking.
